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The impact of new commercial tests evaluating cell-free fetal DNA in maternal circulation for aneuploidy
detection in high-risk patients
Campion, C; Rochon, M.
Lehigh Valley Health Network, Allentown, Pennsylvania

Background
• Fetal aneuploidy is an abnormal number of chromosomes in a fetus’s DNA
caused by missing or extra chromosomes that originate during cell division.
• An abnormal number of chromosomes can result in genetic disorders and
birth defects.
• Three most common types of aneuploidy
– Trisomy 21 (Down syndrome)
– Trisomy 18 (Edwards syndrome
– Trisomy 13 (Patau syndrome)
• Screening for fetal aneuploidy is important in both low-risk and high-risk
pregnancy patients.
• Invasive tests, amniocentesis and chronic villus sampling (CVS), provide the
most accurate information, but are associated with a small risk of miscarriage.
• Non-invasive tests, performed by obtaining maternal blood, are not
associated with a risk of miscarriage but they do not have high accuracy with
detection rates of 70-92% for aneuploidy (1).
• Cell-free fetal DNA (cffDNA), introduced in the fall of 2011, is a new form of
non-invasive aneuploidy tests for the diagnosis of fetal trisomy 13, 18, and 21
– Sensitivities and specificities for the three different aneuploidies approach 100% (2).
•

Results

Results
Figure 1: Primary indication for cffDNA screen

• 958 patients underwent cell-free fetal DNA testing during the
study period. 2 cancelled the test prior to getting results for a
total cohort of 956 patients
Advanced maternal age
Abnormal ultrasound
Abnormal serum screen
Personal/family history

The purpose of this study is to assess how the introduction of cffDNA tests
on a population of high-risk patients from Maternal Fetal Medicine of LVHN
has affected the use of invasive procedures in the practice over a period of
time.

• Advanced maternal age was the most common indication for
testing (Figure 1)
• 13 patients had non-reportable results on initial testing. Of the
12 that were retested, 4 results remained unreportable and
the rest returned negative.
• There were 28 (2.9%) positive and 1 (0.1%) unclassifiable
results (Table 1). The majority of the positive results were
trisomy 21.
• Only 9 patients opted to confirm abnormal results with
invasive testing. All women with confirmed abnormal results
on invasive testing terminated the pregnancy.
• Of the women with positive results, 68% continued the
pregnancy (Table 2).
• Test performance was high (Table 3).
• Cell-free fetal DNA test utilization increased significantly over
time (Figure 2) and was associated with a concomitant
decrease in the number of invasive tests being performed.

Methods
• Retrospective cohort study
• Inclusion criteria:
– Women determined to be at high-risk for aneuploidy seen in Maternal Fetal Medicine at
LVHN from 1/01/2012 to 12/31/13, who underwent cffDNA testing
• Indicatiors of “high-risk”:
– Advanced maternal age (AMA-maternal age ≥ 35)
– Abnormal maternal serum screen
– Abnormal ultrasound findings
– Family/personal history of aneuploidy
*For the results that were confirmed by karyotype
• Exclusion criteria:
Figure 2. Cell-free fetal DNA test utilization over the first two years offered as compared to the utilization of
– Women at low-risk for fetal aneuploidy
• Tests performed during this study period:
invasive procedures
– MaterniT21 Plus (Sequenom CMM)
200
– Verifi Prenatal Test (Verinata)
180
– Harmony Prenatal Test (Integrated Genetics)
• Results were reported as:
160
– Mat21: “positive”, “negative”, or “non-reportable”
140
• Non-reportable results were due to insufficient fetal DNA from
Invasive
maternal serum and women were offered a redraw on an invasive test
Procedures
120
– Verifi: “aneuploidy detected”, “aneuploidy not detected”, or “unclassifiable”
100
• Unclassifiable results are those found to be in the “gray zone” or
cff-DNA
overlap between what is considered positive and negative for a
80
specific aneuploidy
– Women with this result were not offered a redraw per lab protocol
60
but were offered invasive testing
– Harmony: “high-risk” or “low-risk”
40
• Neonatal records and maternal postpartum visit records were reviewed whenever
20
possible to confirm neonatal outcome and identify false positive and/or false
negative results
0
• Descriptive statistics were generated using Excel 2010
Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013
• Utilization of cffDNA as compared to invasive testing over time was determined

Conclusion
• Cell-free fetal DNA (cffDNA) is a new prenatal
aneuploidy screening test being used with increasing
frequency in high risk obstetrical patients
• As utilization of cffDNA is increasing, performance of
invasive (diagnostic) procedures is decreasing
• Although detection rates are much better than older
aneuploidy screening tests, cffDNA should be
considered a screen, not a diagnostic test, as it does
have rare false positive and false negative results. It is
therefore important to confirm positive cffDNA results
with an invasive test.
• Future studies should look at test performance in lowrisk populations.
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